ESD Registry: Endoscopic Submucosal Dissection Registry
Study Details
Study Description
Brief Summary
The purpose of this study is to monitor the success rates and completion rates for endoscopic submucosal dissection (ESD) for gastrointestinal (GI) cancers.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Ease of use of the overall procedure and Time of procedure. [1 Year]
Ease of use of overall procedure as rated on a 5-point visual analog scale for very easy, easy, neutral, difficult and very difficult. Time (in minutes) needed to resect the lesion completely, as measured from the first injection to final excision of the lesion.
Secondary Outcome Measures
- Complications and Rate of Completion [1 Year]
Minor and Major Bleeding Minor and Major perforation Post-polypectomy syndrome (defined as the presence of moderate or severe pain persisting more than 2 hours following completion of the procedure). Other(any other adverse event which the investigator feels is potentially attributable to the procedure). Enbloc resection of all endoscopically visible neoplasia Pathologically negative for lateral and/or deep margins Absence of residual neoplasia confirmed by repeat standard colonscopy and biopsy of ESD site 3-6 months following the index procedure.
Eligibility Criteria
Criteria
Inclusion Criteria: Patients referred for endoscopic treatment of advanced gastrointestinal (colorectal, gastric, duodenal, esophagus) neoplasia, defined by any of the following procedures:
-
Flat dysplastic lesion greater than 2cm(IIa or IIb by Paris classification)
-
Flat depressed lesion < 2cm in size (llc by Paris Classification)
-
Ulcerated lesion < 2cm (Paris type lll) staged as T1N0 on endoscopic ultrasound
-
Upon resection, the criteria for curative ESD include:
-
Non-invasive neoplasia of differentiated carcinoma
-
No lymphovascular invasion
-
Intramucosal cancer or minute submucosal cancer <1 mm invasion (sm1)
-
Negative deep and lateral margins.
Exclusion Criteria:
-
Use of antiplatelet(e.g. clopidrogel) or anticoagulation (e.g. Coumadin) agents that cannot be withheld for at least 7 days prior to the procedure. Aspirin use is accepted according to the American Society for Gastrointestinal Endoscopy for these procedures.
-
Patients who refuse or who are unable to consent.
-
Suboptimal colon prep, or solid gastric residual that precludes safe lesion resection at the time of endoscopy.
-
Lesion location in a segment of the colon not conducive to ESD, including significant narrowing, tortuosity and/or extensive diverticular disease, as determined by the endoscopist.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic Florida | Jacksonville | Florida | United States | 32224 |
Sponsors and Collaborators
- Mayo Clinic
- Olympus
Investigators
- Principal Investigator: Michael B Wallace, MD,MPH, Mayo Clinic
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 10-000160